House over­sight chair calls for in­ves­ti­ga­tion in­to PBM­s' tac­tics to in­crease drug costs

In an­oth­er ef­fort to in­ves­ti­gate phar­ma mid­dle­men and their im­pact on health­care costs, House Over­sight Com­mit­tee Chair James Com­er (R-KY) is launch­ing an in­ves­ti­ga­tion in­to phar­ma­cy ben­e­fit man­agers’ (PBM) “tac­tics that are harm­ing pa­tient care and in­creas­ing costs for con­sumers.”

He’s one of sev­er­al politi­cians who have called for greater trans­paren­cy in­to PBMs, the mid­dle­men who ne­go­ti­ate re­bates with drug­mak­ers in ex­change for for­mu­la­ry cov­er­age.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER